(19)
(11) EP 1 265 635 A1

(12)

(43) Date of publication:
18.12.2002 Bulletin 2002/51

(21) Application number: 01922610.9

(22) Date of filing: 22.03.2001
(51) International Patent Classification (IPC)7A61K 39/395, A61K 45/06, G01N 33/50
// A61K39:395, A61K31:00
(86) International application number:
PCT/US0109/368
(87) International publication number:
WO 0107/0268 (27.09.2001 Gazette 2001/39)
(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 22.03.2000 US 191336 P

(71) Applicant: GLAXO GROUP LIMITED
Greenford, Middlesex UB6 ONN (GB)

(72) Inventors:
  • STIMMEL, Julie BethGlaxo Wellcome Inc.
    Research Triangle Park, NC 27709-3398 (US)
  • THURMOND, Linda MargariteGlaxo Wellcome Inc.
    Research Triangle Park, NC 277009 (US)
  • KNICK, Vincent ClarkGlaxo Wellcome Inc.
    Research Triangle Park, NC 27709 (US)

(74) Representative: Giddings, Peter John, Dr. et al
GlaxoSmithKlineCorporate Intellectual Property (CN9.25.1)980 Great West Road
Brentford,Middlesex TW8 9GS
Brentford,Middlesex TW8 9GS (GB)

   


(54) PHARMACEUTICAL COMPRISING AN AGENT THAT BLOCKS THE CELL CYCLE AND AN ANTIBODY